Clovis Oncology Inc.'s PARP inhibitor Rubraca (rucaparib) has shown a benefit on progression-free survival in the ARIEL3 study in a wider range of ovarian cancer patients than its current label covers. The company will use the data for an sNDA application within the next four months for a second-line and later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who have responded to their most recent platinum therapy.
Shares in Clovis shot up by as much as 45% on Nasdaq on the announcement on the morning of June 19, as analysts suggested they may give Rubraca an edge over rival PARP